{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Amgen, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Amgen, Inc. has recently revised its evaluation amid current market dynamics, with its stock price at $291.16. The company has seen a 7.77% decline over the past year, underperforming compared to the S&P 500. Despite a year-to-date return of 11.71%, Amgen faces challenges in competitive performance.
Is Amgen, Inc. technically bullish or bearish?
As of October 24, 2025, Amgen, Inc. shows a mildly bearish trend with mixed signals from technical indicators, underperforming the S&P 500 year-to-date and over the past year, suggesting caution in the current market environment.
Is Amgen, Inc. technically bullish or bearish?
As of October 24, 2025, Amgen, Inc. shows a mildly bearish trend with mixed technical indicators and underperformed the S&P 500, posting a 1-year return of -7.58% compared to the index's 16.90%.
Is Amgen, Inc. technically bullish or bearish?
As of October 24, 2025, Amgen, Inc. shows a mildly bearish trend overall, with weaker performance compared to the S&P 500, including a 1-year return of -7.58% versus the index's 16.90%.
Amgen's Valuation Shift Signals Potential Growth Opportunities Amid Strong Financial Metrics
Amgen, Inc. has recently experienced a change in its valuation grade, indicating a shift in market perception. Key financial metrics reveal a strong industry position, with a P/E ratio of 22 and a PEG ratio of 0.27, alongside significant operating cash flow and robust management efficiency.
Is Amgen, Inc. overvalued or undervalued?
As of October 17, 2025, Amgen, Inc. is considered undervalued with attractive metrics, including a P/E ratio of 22 and a PEG ratio of 0.27, especially compared to Gilead Sciences, and despite a 7.01% decline in stock price over the past year, it offers a strong ROE of 116.13% and a dividend yield of 3.18%.
Amgen, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics
Amgen, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 22 and a price-to-book value of 25.15. The company demonstrates strong financial metrics, including a high return on equity of 116.13% and a dividend yield of 3.18%, while facing market challenges reflected in its one-year return.
Is Amgen, Inc. overvalued or undervalued?
As of October 17, 2025, Amgen, Inc. is considered undervalued with a P/E ratio of 22 and a PEG ratio of 0.27, outperforming the S&P 500 year-to-date, while its valuation metrics are more favorable compared to peer Gilead Sciences.
Amgen Stock Forms Death Cross, Signaling Potential Bearish Trend Ahead
Amgen, Inc. has recently encountered a technical event known as a Death Cross, indicating potential shifts in market sentiment. Current indicators suggest a bearish outlook, despite a mixed performance over the past year. Investors are watching closely as Amgen shows short-term resilience against broader market trends.
Amgen, Inc. Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators
Amgen, Inc. has recently revised its evaluation amid challenging market dynamics, with its stock showing a slight increase. Over the past year, the company has faced a decline, contrasting with broader market gains. Technical indicators present a mixed outlook, reflecting ongoing efforts to adapt to competitive pressures.
Is Amgen, Inc. technically bullish or bearish?
As of September 19, 2025, Amgen, Inc. has a neutral technical outlook with mixed signals, showing a recent weekly outperformance of 4.23% compared to the S&P 500's 1.22%, but a significant underperformance of -15.23% over the past year versus the S&P's 16.64%.
Is Amgen, Inc. technically bullish or bearish?
As of September 19, 2025, Amgen, Inc. shows a neutral technical trend with mixed indicators, including bearish MACD signals and underwhelming performance compared to the S&P 500, suggesting a cautious outlook.
Amgen Stock Hits Day High with Strong Intraday Performance, Up 3.47%
Amgen, Inc. has shown notable activity, reaching an intraday high of USD 286.15. Despite a decline over the past year, it has achieved a year-to-date increase. The company boasts strong financial metrics, including a return on capital employed of 22.31% and significant operating cash flow.
Is Amgen, Inc. technically bullish or bearish?
As of September 9, 2025, Amgen, Inc. is in a mildly bearish trend, supported by bearish MACD and RSI indicators, despite a slightly bullish daily moving average, and has underperformed the S&P 500 with a 1-year return of -17.15%.
Is Amgen, Inc. overvalued or undervalued?
As of August 5, 2025, Amgen, Inc. is considered undervalued with an attractive valuation grade due to strong financial metrics and a lower P/E ratio compared to peers, despite recent underperformance against the S&P 500.
Is Amgen, Inc. technically bullish or bearish?
As of May 30, 2025, Amgen, Inc. shows a mildly bearish trend due to mixed technical indicators, with recent declines contrasting sharply with the S&P 500's performance.
Is Amgen, Inc. overvalued or undervalued?
As of May 1, 2025, Amgen, Inc. is fairly valued with a P/E ratio of 22, strong growth potential indicated by a PEG ratio of 0.27, and an impressive ROE of 116.13%, making it more favorable than peers like Gilead Sciences and Biogen despite recent underperformance compared to the S&P 500.
Who are in the management team of Amgen, Inc.?
As of March 2022, Amgen, Inc.'s management team includes Chairman and CEO Robert Bradway, Lead Independent Director Robert Eckert, and Independent Directors Wanda Austin, Brian Druker, Gregory Garland, and Fred Hassan.
What does Amgen, Inc. do?
Amgen, Inc. is a large-cap biotechnology company that develops and manufactures human therapeutics, with recent net sales of $8.1 billion and a net profit of $1.7 billion. Key financial metrics include a P/E ratio of 22.00 and a dividend yield of 3.18%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
